Published in Clin J Am Soc Nephrol on March 05, 2008
Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest (2009) 1.27
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res (2011) 1.23
Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia (2014) 0.84
Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats. Br J Pharmacol (2009) 0.81
The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia (2012) 0.77
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med (2003) 23.33
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis (2003) 15.00
Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab (1965) 14.95
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA (2003) 5.33
Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis (1998) 5.28
Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol (2004) 5.23
Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol (2004) 4.79
Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem (1997) 4.77
Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol (2002) 4.52
Assessment of insulin sensitivity in vivo. Endocr Rev (1985) 4.21
Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation (2004) 3.71
Insulin degradation: progress and potential. Endocr Rev (1998) 3.57
MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed (1986) 3.54
The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol (1995) 3.24
Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis (2005) 3.14
Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int (2002) 2.92
Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care (2004) 2.36
Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis (2005) 2.30
Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol (2001) 2.22
Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int (1999) 2.13
Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care (2005) 1.88
A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes (1994) 1.73
Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care (2006) 1.70
Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol (2003) 1.70
Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int (2000) 1.62
The role of leptin in human physiology. N Engl J Med (1999) 1.55
Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes (2004) 1.51
The human glomerular podocyte is a novel target for insulin action. Diabetes (2005) 1.49
Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis (2006) 1.46
Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes (1998) 1.45
Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol (1999) 1.37
High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes (2007) 1.32
Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabet Med (1988) 1.29
Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care (2002) 1.25
Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int (2002) 1.20
Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int (2001) 1.10
Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int (1998) 1.05
Comparison of the minimal model and the hyperglycemic clamp for measuring insulin sensitivity and acute insulin response to glucose. Metabolism (1995) 1.01
Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol (1997) 1.00
The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens (2006) 0.98
Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int (1994) 0.89
Automated determination of urinary creatinine without sample dilution: theory and practice. Clin Chem (1986) 0.84
Changing glomerular filtration with progression from impaired glucose tolerance to Type II diabetes mellitus. Diabetologia (1999) 0.83
Insulin's acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin's acute effects on proximal tubular sodium reabsorption correlation with salt sensitivity in normal subjects. Nephrol Dial Transplant (1999) 0.82
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care (2003) 5.27
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care (2004) 3.51
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab (2003) 3.04
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem (2005) 2.98
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care (2002) 2.92
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76
Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A (2009) 2.73
Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.63
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 2.51
Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol (2003) 2.51
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes (2006) 2.40
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes (2003) 2.22
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care (2002) 2.16
Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care (2008) 2.12
Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol (2003) 2.12
Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.08
Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2004) 2.08
Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. Ann Epidemiol (2009) 2.07
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis (2008) 2.02
Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev (2007) 1.98
Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol (2003) 1.91
Dyslipidemia management in adults with diabetes. Diabetes Care (2004) 1.89
Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes (2009) 1.87
Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes (2003) 1.81
Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab (2009) 1.81
NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol (2009) 1.80
Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes (2007) 1.79
Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care (2009) 1.78
Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study. Diabetes (2008) 1.78
Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism (2005) 1.77
Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab (2007) 1.76
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75
Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care (2004) 1.74
Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med (2005) 1.71
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
Is prehypertension a risk factor for the development of type 2 diabetes? Diabetes Care (2009) 1.67
Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care (2003) 1.66
Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr (2006) 1.65
Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND). Diabetes (2007) 1.61
AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem (2010) 1.60
Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens (2009) 1.60
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes (2004) 1.55
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes (2011) 1.53
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab (2009) 1.52
Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res (2002) 1.52
Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes (2004) 1.51
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49
Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2007) 1.49
Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finnish offspring of type 2 diabetic individuals. J Clin Endocrinol Metab (2010) 1.49
Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation. Am J Physiol Renal Physiol (2002) 1.45
Isolated hyperglycemia at 1 hour on oral glucose tolerance test in pregnancy resembles gestational diabetes mellitus in predicting postpartum metabolic dysfunction. Diabetes Care (2008) 1.41
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.41
A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care (2010) 1.41
Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation (2002) 1.41
Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care (2009) 1.40
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich) (2012) 1.40
Management of dyslipidemia in adults with diabetes. Diabetes Care (2003) 1.39
Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes (2002) 1.38
NAD(P)H oxidases regulate HIF-2alpha protein expression. J Biol Chem (2007) 1.37
Analysis of FTO gene variants with measures of obesity and glucose homeostasis in the IRAS Family Study. Hum Genet (2009) 1.36
A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care (2003) 1.33
Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation (2003) 1.32
Involvement of calcineurin in transforming growth factor-beta-mediated regulation of extracellular matrix accumulation. J Biol Chem (2004) 1.32
Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J (2004) 1.31